

OPTIMIND PHARMA CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED NOVEMBER 30, 2025 AND 2024
(Unaudited- expressed in Canadian Dollars)

NOTICE TO READER

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited consolidated interim financial statements have been prepared by and are the responsibility of management.

The Company's independent auditor has not performed a review of these consolidated interim financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

OPTIMIND PHARMA CORP.

Table of contents

Cover	1
Table of contents	2
Interim Consolidated Statements of Financial Position (unaudited)	3
Interim Consolidated Statement of Loss and Comprehensive Loss (unaudited)	4
Interim Consolidated Statement of Changes in Shareholders' Equity (Deficiency) (unaudited)	5
Interim Consolidated Statement of Cash Flows (unaudited)	6
Notes to the Condensed Interim Consolidated Financial Statements	7-24

Optimind Pharma Corp.

Interim Consolidated Statements of Financial Position

(in Canadian dollars)

(Unaudited)

ASSETS	November 30, 2025	February 28, 2025
CURRENT		
Cash	\$ 93,912	\$ 83,774
Accounts receivable	47,637	35,706
Sales tax receivable	-	30,654
	141,549	150,134
Equity Investments (Note 14)	50,000	50,000
TOTAL ASSETS	\$ 191,549	\$ 200,134
LIABILITIES AND SHAREHOLDERS' DEFICIENCY		
LIABILITIES		
CURRENT		
Accounts payable and accrued liabilities	\$ 179,691	\$ 149,326
Convertible debentures (Note 11)	120,637	125,637
	300,328	274,963
Deferred tax liability (Notes 11)	-	-
TOTAL LIABILITIES	300,328	274,963
SHAREHOLDERS' DEFICIENCY		
Share capital (Note 10(a))	4,798,743	4,792,943
Contributed surplus (Note 11)	8,674	8,674
Share based payment reserve (Note 10(b))	162,400	162,400
Accumulated deficit	(5,078,596)	(5,038,846)
TOTAL SHAREHOLDERS' DEFICIENCY	(108,779)	(74,829)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIENCY	\$ 191,549	\$ 200,134

Organization and nature of operations (Note 1)
Basis of presentation and going concern (Note 2)

Approved on behalf of the Board of Directors:

/s/ "David Goodman"
David Goodman, Director

/s/ "David Yu"
David Yu, Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Optimind Pharma Corp.**Interim Consolidated Statements of Loss and Comprehensive Loss**

For the periods ended:

(in Canadian dollars)

(Unaudited)

	For the three months ended November 30, 2025	For the three months ended November 30, 2024	For the nine months ended November 30, 2025	For the nine months ended November 30, 2024
Revenue	\$ 34,025	\$ 26,557	\$ 96,780	\$ 83,668
Expenses:				
Consulting fees (Note 12)	9,930	8,300	35,720	185,300
Contract work	18,742	10,821	41,066	36,306
Computer and software expenses	2,502	550	3,652	1,436
Legal and professional expenses	15,800	4,303	20,140	10,019
Office and general	6,461	9,375	20,622	30,450
Transfer agent and regulatory fees	9,210	2,251	15,330	9,265
Total Operating expenses	\$ (62,645)	\$ (35,600)	\$ (136,530)	\$ (272,776)
Loss before income taxes	\$ (28,620)	\$ (9,043)	\$ (39,750)	\$ (189,108)
Income tax	-	-	-	-
Loss and comprehensive loss	\$ (28,620)	\$ (9,043)	\$ (39,750)	\$ (189,108)
 Loss per share-Basic and Diluted	\$ (0.0003)	\$ (0.0001)	\$ (0.0004)	\$ (0.0017)
Weighted average number of shares outstanding-Basic and Diluted	103,148,491	109,788,491	103,615,255	111,973,582

The accompanying notes are an integral part of these condensed interim consolidated financial statements

Optimind Pharma Corp.**Interim Statements of Changes in Shareholders' Equity (Deficiency)**

(in Canadian dollars)

(Unaudited)

	Number of common shares outstanding	Share capital	Contributed Surplus	Share- based compensation reserve	Deficit	Total
Balance as of February 29, 2024	116,888,491	\$ 4,522,943	\$ 8,674	\$ 162,400	\$ (4,823,034)	\$ (129,017)
Cancellation of shares	(12,500,000)	-	-	-	-	-
Private placement of shares	5,400,000	270,000	-	-	-	270,000
Net loss for the period	-	-	-	-	(189,108)	(189,108)
Balance as at November 30, 2024	109,788,491	\$ 4,792,943	\$ 8,674	\$ 162,400	\$ (5,012,142)	\$ (48,125)
Balance as of February 28, 2025	109,788,491	\$ 4,792,943	\$ 8,674	\$ 162,400	\$ (5,038,846)	\$ (74,829)
Cancellation of shares	(7,000,000)	-	-	-	-	-
Shares issued for services	160,000	800	-	-	-	800
Shares issued on conversion of convertible debentures	200,000	5,000	-	-	-	5,000
Net loss for the period	-	-	-	-	(39,750)	(39,750)
Balance as at November 30, 2025	103,148,491	\$ 4,798,743	\$ 8,674	\$ 162,400	\$ (5,078,596)	\$ (108,779)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

Optimind Pharma Corp.
Interim Consolidated Statements of Cash Flows
For the periods ended:
(in Canadian dollars)
(Unaudited)

	November 30, 2025	November 30, 2024
OPERATING ACTIVITIES		
Net loss	\$ (39,750)	\$ (189,108)
Non-cash items included in net loss and other adjustments:		
Issue of common shares for services	800	-
Changes in non-cash working capital:		
Accounts receivables	(11,931)	(2,852)
Sales tax receivable	30,654	102,004
Accounts payable and accrued liabilities	30,365	(106,161)
CASH FROM (USED IN) OPERATING ACTIVITIES	10,138	(196,117)
FINANCING ACTIVITIES		
Private placement of shares	-	270,000
CASH PROVIDED (USED) BY FINANCING ACTIVITIES	-	270,000
NET CHANGE IN CASH DURING THE PERIOD	10,138	73,883
CASH, BEGINNING OF PERIOD	83,774	28,696
CASH, END OF PERIOD	\$ 93,912	\$ 102,579
Cash consists of:		
Cash	\$ 10,138	\$ 102,579
Restricted cash	\$ -	-
	\$ 10,138	\$ 102,579
Cash paid for interest and income taxes	\$ -	\$ -

Non-cash transactions:

The following were non-cash transactions during the nine-month period ended November 30, 2025:

- (a) The Company issued 160,000 common shares fair valued at \$ 800 for services.
- (b) 200,000 common shares issued at \$0.025 per share for conversion of \$5,000 convertible debt

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

1. Organization and Nature of Operations

Optimind Pharma Corp., formerly Loon Energy Corporation, ("Optimind" or the "Company") was incorporated pursuant to the provisions of the Business Corporation Act (Alberta) on October 30, 2008 in conjunction with the reorganization by legal plan of arrangement of Loon Energy Inc. ("Loon") and on November 23, 2021 under the laws of Ontario respectively. On July 28, 2022, the Company completed a triangular amalgamation (the "Transaction") with its wholly owned subsidiary 1000033135 Ontario Inc. and Optimind Pharma Inc. ("OPI"), a private company incorporated under the Province of Ontario. During the transaction, the Company acquired all of the issued and outstanding shares of OPI (the "Target Shares") by share exchange, including Redytogo Limited which is 100% owned by OPI. All of the Target Shares were exchanged on the basis of one common share of the Company for one Target Share. To facilitate the execution of the transaction, on November 23, 2021 the Company incorporated 1000033135 Ontario Inc (the "Subsidiary"). Prior to the Amalgamation, the Company completed a share consolidation of its outstanding common shares on a 1.713084 for one basis. After the share consolidation, the Company issued 8,649,983 of the resulting issuer's common shares to the former shareholders of Loon Energy Corporation.

Loon Energy Corporation's shares were listed on the TSX Venture exchange ("TSX.V"). At the Company's request, Loon Energy Corporation's shares were delisted from the TSX.V on June 24, 2022. On August 4, 2022, the Company's shares began trading on the Canadian Securities Exchange ("CSE") under the symbol OMND. The Company's corporate head office is located at 77 King Street W, Suite 3000, Toronto, Ontario, Canada, M5K 1G8. The Board of Directors of the Company authorized these financial statements for issuance on January 29, 2025.

2. Basis of Presentation and Going Concern**Basis of Preparation**

These condensed interim financial statements have been prepared on the historical cost basis except for financial instruments recorded at fair value. In addition, these interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information. The functional currency of the Company is the Canadian dollar, which is also the Company's reporting currency.

Statement of Compliance

These condensed interim consolidated financial statements (the "Financial Statements") are unaudited and have been prepared on a condensed basis in accordance with International Accounting Standard 34, Interim Financial Reporting issued by the International Accounting Standards Board ("IASB"), using accounting policies of International Financial Reporting Standards ("IFRS") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC. The condensed interim financial statements should be read in conjunction with the annual audited financial statements for the year ended February 28, 2025, which have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board ("IASB"). The unaudited condensed interim financial statements are based on accounting policies as described in the February 28, 2025 audited financial statements.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

2. Basis of Presentation and Going Concern (Cont'd)**Going Concern Assumption**

These financial statements have been prepared using IFRS on a going concern basis, which presumes the realization of assets and discharge of liabilities in the normal course of business, for the next fiscal year. At November 30, 2025, the Company had cash of \$93,912, a working capital deficit of \$206,416 and an accumulated deficit of \$5,078,596. The continuing operations of the Company are dependent on funding provided by equity investors. The Company intends to finance its future requirements through a combination of equity and/or debt issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favorable terms.

These uncertainties may cast significant doubt about the ability of the Company to continue as a going concern. These financial statements do not include any adjustments to the carrying value or presentation of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. These adjustments could be material.

Significant Accounting Judgments and Estimates

The preparation of these financial statements in compliance with IFRS requires management to make certain critical accounting estimates and assumptions. These estimates and assumptions affect the reported amounts of assets, liabilities, shareholders' equity, and the disclosure of contingent assets and liabilities, as at the date of the financial statements, and expenses for the period reported.

Critical Judgements

The preparation of these financial statements requires management to make judgements regarding the going concern of the Company (discussed above), as well as the determination of functional currency. The functional currency is the currency of the primary economic environment in which an entity operates. The functional currency for the Company has been determined to be the Canadian dollar.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

2. Basis of Presentation and Going Concern (Cont'd)**Significant Accounting Judgments and Estimates (Cont'd)**Critical Judgements (Cont'd)Key Sources of Estimation Uncertainty

Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates and such differences could be significant.

Significant estimates made by management affecting the financial statements include:

Deferred tax assets & liabilities

The estimation of income taxes includes evaluating the recoverability of deferred tax assets and liabilities based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probable that some or all of the deferred income tax assets and liabilities will not be realized. The ultimate realization of deferred tax assets and liabilities is dependent upon the generation of future taxable income. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets or liabilities, and deferred income tax provisions or recoveries could be affected.

Determination of Purchase Price Allocation

Estimates are made in determining the fair value of assets and liabilities, including the valuation of separately identifiable intangibles acquired as part of an acquisition. Management exercises judgment in estimating the probability and timing of when cash flows are expected to be achieved, which is used as the basis for estimating fair value. Future performance results that differ from management's estimates could result in changes to liabilities recorded, which are recorded as they arise through profit or loss. The fair value of identified intangible assets is determined using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Acquisitions that do not meet the definition of a business combination are accounted for as asset acquisitions. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Asset acquisitions do not give rise to goodwill.

Useful life of intangible assets

The intangible asset is depreciated over its estimated useful life. Estimated useful lives are determined based on current facts and past experience and takes into consideration the anticipated life of the asset, the potential for technological obsolescence, and regulations.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

2. Basis of Presentation and Going Concern (Cont'd)**Significant Accounting Judgments and Estimates (Cont'd)***Impairment of goodwill and other intangible assets*

The impairment assessment associated with goodwill and other intangible assets involve significant estimates and assumptions, including those with respect to the determination of cash generating units ("CGUs"), future cash inflows and outflows, discount rates and useful asset lives. At least annually, the carrying amount of goodwill and other intangible assets are reviewed for potential impairment. Among other things, this review considers the recoverable amounts of the CGUs based on the higher of value in use or fair value less costs of disposal using discounted estimated future cash flows. These significant estimates require considerable judgment which could affect the Company's future results if the current estimates of future performance and fair value change.

Impairment of investment in associate

The impairment assessment for the investment in associate involves significant estimates and assumptions. At least annually, the carrying amount investment in associate is reviewed for potential impairment. Among other things, this review considers the recoverable amounts of the associate based on the higher of value in use or fair value less costs of disposal using discounted estimated future cash flows. These significant estimates require considerable judgment which could affect the Company's future results if the current estimates of future performance and fair value change.

Leases

The Company estimates the lease term by considering the facts and circumstances that can create an economic incentive to exercise an extension option or not exercise a termination option by assessing relevant factors such as store profitability. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated). The assessment of the lease term is reviewed if a significant event or a significant change in circumstance occurs, which affects this assessment and is within the control of the lessee. The Company estimates the incremental borrowing rate used to measure our lease liability for each lease contract. This includes estimation in determining the asset-specific security impact.

Share-based payments

Estimating fair value for granted stock options requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the option, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

3. Significant Accounting Policies

The accounting policies set out in the financial statements for the year ended February 28, 2025, have been applied consistently to all periods presented in these interim financial statements.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

4. Investment in Associates

Manitari Pharma Inc. ("Manitari")

In May 2021, the Company acquired 40% ownership of Manitari which made the Company to have significant influence over Manitari's operations, but not control. The financial results of Manitari will be included in the Company's results according to the equity method.

The consideration transferred for the 40% ownership included 7,000,000 common shares of the Company and \$100,000 of cash. The 7,000,000 common shares were valued at \$210,000. Manitari has applied for a Psilocybin dealers license to produce Psilocybin for use in micro doses in-clinic for Psilocybin-PEP, will be accessible to qualified non-native patients through North America. As at February 28, 2023, the management impaired the investment in Manitari to nil due to lack of revenue.

As at February 29, 2024, the Company had advanced cash of \$193,357 to Manitari to finance Manitari's operation. The cash advance had been recorded as loan to related party during the year ended February 29, 2024. This loan is unsecured, non-interest bearing and due on demand. As of February 29, 2024, the Company impaired the loan of \$193,357.

In March 2025, the Company relinquished its 40% equity interest in Manitari and forgave the funds advanced by the Company to Manitari, in exchange for the cancellation of 7 million Optimind Shares previously issued to a shareholder of Manitari (Note 10).

5. Equity Investment

The Company has a 1% interest in the outstanding shares of Beatrice Society Holdings Inc., ("Beatrice"), a private corporation incorporated under the laws of the Province of Ontario and does not have any significant influence over Beatrice's operations.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

6. Acquisition of Mindsetting Institute

On September 16, 2022, Optimind completed the acquisition of Mindsetting Institute, a leader in psychedelic enhanced therapy training and educational programming. In consideration for the acquisition, the Company issued a total of 22,500,000 common shares for a total consideration of \$371,250 (the "Purchase Price"), which shares are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. The MindSetting assets acquired by Optimind include course modalities, including fully asynchronous, online synchronous and hybrid learning opportunities.

At the time of the Transaction, Mindsetting did not constitute a business as defined under IFRS 3 – business combinations, and therefor the Transaction is accounted for as an asset acquisition. Management assessed that it is very likely that Mindsetting Institute will meet the earn-out milestones on time and recognized 11,500,000 common shares for earn-out as the acquisition cost. Management recognized the Intangible-Mindsetting at value of \$371,250.

The following table summarizes the fair value of consideration paid on the acquisition date and the allocation of the Purchase Price.

Consideration

22,500,000 Common Shares	\$	371,250
--------------------------	----	---------

Purchase Price allocation

Intangible-Mindsetting	\$	371,250
------------------------	----	---------

During the year ended February 29, 2024, the Company recorded impairment in intangible assets for \$371,250.

In June 2024, the Company cancelled 12,500,000 common shares issued to Mindsetting pursuant to the mutual release (Note 10).

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

7. Intangible Assets

	Mindsetting
	\$
Cost:	
February 28, 2023	371,250
Impairment	(371,250)
February 29, 2024, February 28, 2025 and November 30, 2025	-
Net Book Value:	
At November 30, 2025	-
At February 28, 2025	-

As at February 29, 2024, the Company recorded an impairment of its intangible asset for Mindsetting totaling \$371,250 due to the lack of revenues.

8. Right-of-use Asset

The following shows the movement of the Company's right-of-use assets.

	Right of Use Asset
	\$
Cost:	
February 28, 2023	149,645
Additions	-
February 28, 2025 and November 30, 2025	149,645
Accumulated amortization:	
February 28, 2023	54,869
Early termination of lease	74,824
Charge for the period	19,952
February 28, 2025 and November 30, 2025	149,645
Net Book Value:	
At November 30, 2025	-
At February 28, 2025	-

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

9. Lease Liability

At the commencement date of the lease, the lease liability was measured at the present value of the lease payments that were not paid at that date. The lease payments are discounted using an interest rate of 18% which is the Company's incremental borrowing rate.

	\$
February 28, 2022	132,999
Accretion on lease obligation	22,060
Lease payments made	(45,600)
February 28, 2023	109,459
Accretion on lease obligation	12,201
Early termination of lease	91,260
Lease payments made	(30,400)
February 29, 2024, February 28, 2025 and November 30, 2025	-

10(a) Capital Stock

The Company is authorized to issue the following shares:

- Unlimited number of common shares

Common shares

The holders of common shares are entitled to receive dividends which are declared from time to time and are entitled to one vote per share at meetings of the Company. All shares are ranked equally with regards to the Company's residual assets.

At November 30, 2025, the Company has 103,148,491 common shares issued and outstanding.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

10(a) Capital Stock (Cont'd)**Share issuances**During the nine- month period ended November 30, 2025

- In March 2025, the Company relinquished its 40% equity interest in Manitari and forgave the funds advanced by the Company to Manitari, in exchange for the cancellation of 7 million Optimind Shares previously issued to a shareholder of Manitari.
- The Company issued 160,000 shares fair valued at \$800 for services.
- The Company issued 200,000 shares at \$0.025 per share for conversion of \$5,000 convertible debt.

During the year ended February 28, 2025

- Pursuant to the mutual release effective January 31, 2024, the Company cancelled 12,500,000 common shares, issued as part consideration for the acquisition of assets of Mindsetting Institute (Note 6)
- On July 8, 2024, the Company announced that it closed the first tranche of its private placement for issuance of 2,900,000 common shares at a price of \$0.05 per share for gross proceeds of \$145,000.
- On July 29, 2024, the Company announced it closed the second tranche of its private placement for issuance of 2,500,000 common shares at a price of \$0.05 per share for gross proceeds of \$125,000.

As at November 30, 2025 and February 28, 2025, the Company has no outstanding warrants.

10(b) Share based compensation

The Company has established a stock option plan whereby officers, directors, employees and service providers may be granted options to purchase common shares at a fixed price. Vesting and expiry provisions are determined at the date of grant. The plan provides for the issuance of stock options to acquire up to 10% of the Company's issued and outstanding capital. The plan is a rolling plan as the number of shares reserved for issuance pursuant to the grant of stock options will increase as the Company's issued and outstanding share capital increases.

During the period ended November 30, 2025

The Company did not issue any options during the period ended November 30, 2025.

During the year ended February 28, 2025

The Company did not issue any options during the year ended February 28, 2025

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements
For the nine months ended November 30, 2025 and 2024
(in Canadian dollars)
(Unaudited)

10(b) Share based compensation (Cont'd)

Continuity of the Company's options is as follows:

	Number of Options	Weighted Average Exercise Price
Outstanding, February 29, 2024	5,900,000	\$0.05
Granted	-	-
Expired	-	-
Exercised	-	-
Outstanding February 28, 2025 and November 30, 2025	5,900,000	\$0.05

As at November 30, 2025, the Company had the following share purchase options outstanding and exercisable:

Number of options Outstanding	Exercisable	Exercise Price	Remaining Life (Years)	Expiry Date
5,900,000	5,900,000	\$0.05	1.27	March 8, 2027

11. Convertible debentures

During the year ended February 28, 2022, the Company received convertible debentures for \$507,000 with mature date on January 28, 2024 and 10% interest per annum payable on maturity.

Effective January 28, 2024, convertible debentures of face value of \$397,750 along with accrued interest of \$59,663, for a total consideration of \$457,413 were converted into 18,296,500 common shares at \$0.025 per share. \$31,578 of equity component of the Debentures were also transferred to share capital.

During the year ended February 28, 2025, the Company recorded \$nil interest (2024: \$46,475) and \$nil deferred tax recovery in the consolidated statements of loss and comprehensive loss.

During the nine-month period ended November 30, 2025, the Company issued 200,000 shares on conversion of \$5,000 convertible debt at \$0.025 per share.

As at November 30, 2025, the remaining convertible debentures and accrued interest totaling \$120,637 were in default (February 28, 2025: \$125,637).

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

11. Convertible debentures (Cont'd)

As at November 30, 2025, the Company's Debentures were comprised of the following:

		Equity component of convertible debenture		Liability component of convertible debenture
Balance, February 28, 2023	\$	40,252	\$	503,951
Accrued interest		-		46,046
Accretion expenses		-		33,053
Conversion into common shares		(31,578)		(457,413)
Balance, February 29, 2024 and February 28, 2025	\$	8,674	\$	125,637
Conversion into common shares		-		(5,000)
Balance, November 30, 2025	\$	8,674	\$	120,637

12. Related Party Transactions

Related parties include key management personnel, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Key management of the Company are the Chief Executive Officer ("CEO") the Chief Financial Officer ("CFO") and the Chief Operating officer ("COO").

Transactions with key management personnel not disclosed elsewhere in the financial statements include the following:

		Nine months ended November 30, 2025		Nine months ended November 30, 2024
Consulting fees expensed to directors and officers	\$	34,920	\$	34,300
	\$	34,920	\$	34,300

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

12. Related Party Transactions (Cont'd)

	Three months ended November 30, 2025	Three months ended November 30, 2024
Consulting fees expensed to directors and officers	\$ 9,930	\$ 16,605
	\$ 9,930	\$ 16,605

13. Financial Instruments

The Company's financial instruments consist of cash, accounts receivable, accounts payable and convertible debentures. The fair value of the Company's accounts receivable and accounts payable approximate carrying value, due to their short-term nature. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities.

Financial risk management and objectives

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, and market risk (including interest rate risk, foreign currency risk, and commodity price risk).

The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. Where material, these risks are reviewed and monitored by the Board of Directors.

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk as during the nine-month period ended November 30, 2025, 100% of its revenue was from four customers (November 30, 2024: 96% from three customers).

Liquidity risk

Liquidity risk is the risk that the Company will not have sufficient cash resources to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital market is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company generates cash flows primarily from its financing activities.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

13. Financial Instruments (Cont'd)**Financial risk management and objectives (Cont'd)**

The Company manages its liquidity needs by carefully monitoring scheduled costs. Liquidity is measured in various time bands, on day to day and week-to-week basis, as well as on long term liquidity needs over 180 day to 360 day look out periods. Funding for long-term liquidity needs is based on the ability of the Company to successfully complete private placements.

As at November 30, 2025, the Company had unrestricted cash of \$93,912 to settle current liabilities of \$300,328.

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, equity prices, and foreign exchange rates.

(a) Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk.

(b) Price risk

The Company is not exposed to significant price risk as it does not possess investments in publicly traded securities.

(c) Currency risk

Currency risk is the risk that the fair value of future cash flows of a financial instrument denominated in a foreign currency will fluctuate because of changes in foreign exchange rates. The Company is not exposed to significant current risk.

14. Capital Management

The Company considers its capital to be shareholders' equity, which is comprised of share capital and deficit, which as at November 30, 2025 totaled a deficiency of \$. The Company's capital structure is adjusted based on the funds available to the Company such that it may continue to seek new opportunities.

The Board of Directors does not establish quantitative return on capital criteria but rather relies on the expertise of management and other professionals to sustain future development of the business. The sources of future funds presently available to the Company are through the sale of equity capital of the Company. The ability of the Company to arrange such financing in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Company.

Optimind Pharma Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the nine months ended November 30, 2025 and 2024

(in Canadian dollars)

(Unaudited)

14. Capital Management (Cont'd)

There can be no assurance that the Company will be successful in its efforts to arrange additional financing, if needed, on terms satisfactory to the Company. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company is not subject to externally imposed capital restrictions.

15. Segment Information

The Company is in the business of non-OHIP treatment operations, including ketamine treatments and cannabis referrals.

For the nine-month periods ended November 30, 2025 and 2024, the Company's entire revenue comprises of ketamine and cannabis referrals. All assets are located in Canada.

16. Material agreements

The Company entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") which will change the business of the Company to a technology company focused on artificial intelligence (the "Resulting Issuer") constituting a "Fundamental Change" of the Company under the policies of the Canadian Securities Exchange (the "CSE").

Pursuant to the SEA, the Company will issue an aggregate of 11,000,000 common shares (on a post Consolidated basis as discussed below) of the Company ("Company Shares"). Following closing of the Transaction, the Company will issue an additional 3,000,000 Company Shares to the two principals of InterviewDesk over two years (1,500,000 Company Shares on each of the first and second anniversary of closing). Immediately prior to closing of the Transaction, the Company would consolidate (the "Consolidation") its existing common shares on one (1) new share for approximately 3.66 old shares, such that after the Consolidation but prior to completion of the Transaction and the Concurrent Financing, the Company shall have 30,000,000 Company Shares issued and outstanding. Upon completion of the Transaction, InterviewDesk will become a wholly owned subsidiary of the Resulting Issuer. A finder's fee of 5,000,000 Company Shares is payable in connection with the Transaction.